BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM) is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. Metabolic Program consists of ThermoStem(R), developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative Therapies, Inc. is based in Melville, New York.
| Revenue (Most Recent Fiscal Year) | $0.40M |
| Net Income (Most Recent Fiscal Year) | $-8.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 20.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.39 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1772.40% |
| Net Margin (Trailing 12 Months) | -1772.40% |
| Return on Equity (Trailing 12 Months) | -137.00% |
| Return on Assets (Trailing 12 Months) | -88.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.23 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.27 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.98M |
| Free Float | 5.52M |
| Market Capitalization | $12.29M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | -0.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 30.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.38% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |